Introduction

Cell proliferation assays are pivotal for understanding the growth dynamics and viability of cancer cells, providing essential insights into the efficacy of potential therapeutics. The human colon adenocarcinoma cell line HCT-15 is an extensively studied model for colorectal cancer research, offering invaluable data through various assay techniques. As a seasoned biological specialist at Creative Biolabs, we provide comprehensive solutions for HCT-15-based proliferation assays, backed by cutting-edge technology and robust scientific methodologies.

Human Colon Cell HCT-15-based Proliferation Assay at Creative Biolabs

At Creative Biolabs, we specialize in leveraging the HCT-15 human colon cell line for proliferation assays. HCT-15 cell line is derived from human colon adenocarcinoma and represents a key model in oncology for investigating tumor cell growth and response to treatments. Our assays are designed with precision to deliver high-throughput and reliable results, essential for both basic research and advanced drug development.

Service Contents

Creative Biolabs offers a diverse portfolio of proliferation assays tailored to meet specific research needs, such as MTT Assay, WST Assay, etc. Currently, Luminescent Cell Viability Assay is a premier method employed at Creative Biolabs. This highly sensitive, homogeneous assay leverages firefly luciferase to oxidize D-Luciferin in the presence of ATP, generating light proportional to the number of viable cells. This assay is particularly suited for high-throughput screening due to its straightforward "add-mix-measure" protocol.

Our standard procedure for HCT-15-based assays involves pre-incubating these cells in 96-well plates under optimized conditions. Following an overnight incubation, test compounds or vehicles are administered, and the cells are incubated for an additional 72 hours. Finally, luminescent readouts are achieved.

Sample Compatibility

• Cell types: our assays are compatible with both suspension cell and adherent cell types.
• Test sample requirements:

For screening assays, we accept 25 μl of a 10 mM stock solution or 1 mg pre-weighed samples.

For dose-response studies, 60 μl of 10 mM stock or 1 mg pre-weighed samples are required.

Benefits for You

Creative Biolabs delivers a comprehensive service package with distinguishing features:

• High Sensitivity and Specificity: Utilizing luminescence-based detection methods to ensure precise measurement of cell proliferation and viability.
• Flexible Formats: Assays are adaptable to various scales, from single-well studies to large-scale high-throughput screens.
• Comprehensive Analysis: Detailed reporting of growth inhibition (GI50), total growth inhibition (TGI), and 50% lethal concentration (LC50), tailored to meet research needs.

Scientific Backing

HCT-15 is often used as a common cell line model to study the inhibitory effect of anticancer drugs in colorectal cancer. For example, a study published in Clinical Cancer Research evaluated that roburic acid is a novel drug targeting TNF in the treatment of colorectal cancer.

Fig.1 Roburic acid showed proliferation inhibition on human colorectal cancer cells.¹

Frequently Asked Questions

Q1: What makes HCT-15 cells suitable for proliferation assays?

A1: HCT-15 cells are derived from human colon adenocarcinoma, providing a clinically relevant model to study colorectal cancer's molecular biology and response to treatments.

Q2: How does luminescent detection enhance assay sensitivity?

A2: Luminescent detection measures ATP levels, directly correlating with cell viability. This method is highly sensitive, capable of detecting low cell numbers, and producing consistent, reproducible results.

Q3: What kind of controls are used in these assays?

A3: Standard controls include vehicle-treated cells and known inhibitors like Staurosporine to validate the assay's accuracy and consistency.

At Creative Biolabs, our expertise and advanced methodologies in HCT-15-based proliferation assays ensure high-quality data generation for comprehensive analysis and drug development in colorectal cancer research.

Reference

1. Xu, Huanhuan, et al. "Roburic acid targets TNF to inhibit the NF-κB signaling pathway and suppress human colorectal cancer cell growth." Frontiers in Immunology 13 (2022): 853165. Distributed under Open Access License CC BY 4.0, without modification.

For Research Use Only | Not For Clinical Use